Suppr超能文献

相似文献

1
Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond.
Immunology. 2014 Jul;142(3):347-53. doi: 10.1111/imm.12272.
2
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6. doi: 10.1073/pnas.1014154108. Epub 2010 Dec 21.
3
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Br J Pharmacol. 2009 Nov;158(5):1173-82. doi: 10.1111/j.1476-5381.2009.00451.x. Epub 2009 Oct 8.
4
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101. doi: 10.1097/WNF.0b013e3181cbf825.
5
Sphingosine-1-phosphate and immune regulation: trafficking and beyond.
Trends Pharmacol Sci. 2011 Jan;32(1):16-24. doi: 10.1016/j.tips.2010.11.002. Epub 2010 Dec 14.
7
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Neurology. 2011 Feb 22;76(8 Suppl 3):S3-8. doi: 10.1212/WNL.0b013e31820d5ec1.
8
Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.
Cell Signal. 2014 Jul;26(7):1576-88. doi: 10.1016/j.cellsig.2014.03.029. Epub 2014 Apr 2.
9
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Neurology. 2011 Feb 22;76(8 Suppl 3):S20-7. doi: 10.1212/WNL.0b013e31820db341.

引用本文的文献

2
The critical roles of bioactive sphingolipids in inflammation.
J Biol Chem. 2025 Jul 11;301(8):110475. doi: 10.1016/j.jbc.2025.110475.
4
A blood-based mRNA signature distinguishes people with Long COVID from recovered individuals.
Front Immunol. 2024 Dec 3;15:1450853. doi: 10.3389/fimmu.2024.1450853. eCollection 2024.
6
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management.
Drugs. 2024 Oct;84(10):1179-1197. doi: 10.1007/s40265-024-02094-5. Epub 2024 Sep 26.
7
Fatty acid oxidation in immune function.
Front Immunol. 2024 Jun 27;15:1420336. doi: 10.3389/fimmu.2024.1420336. eCollection 2024.
10
Drug resistance in glioblastoma: from chemo- to immunotherapy.
Cancer Drug Resist. 2023 Oct 11;6(4):688-708. doi: 10.20517/cdr.2023.82. eCollection 2023.

本文引用的文献

1
Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells.
Nat Immunol. 2013 Dec;14(12):1285-93. doi: 10.1038/ni.2745. Epub 2013 Oct 27.
3
The integration of T cell migration, differentiation and function.
Nat Rev Immunol. 2013 May;13(5):309-20. doi: 10.1038/nri3442. Epub 2013 Apr 19.
4
Sphingosine-1-phosphate and its receptors: structure, signaling, and influence.
Annu Rev Biochem. 2013;82:637-62. doi: 10.1146/annurev-biochem-062411-130916. Epub 2013 Mar 18.
5
Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs.
Annu Rev Immunol. 2012;30:69-94. doi: 10.1146/annurev-immunol-020711-075011. Epub 2011 Dec 5.
6
GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood.
Science. 2011 Sep 30;333(6051):1898-903. doi: 10.1126/science.1208248.
7
Regional and mucosal memory T cells.
Nat Immunol. 2011 Jun;12(6):485-91. doi: 10.1038/ni.2029.
8
The outs and the ins of sphingosine-1-phosphate in immunity.
Nat Rev Immunol. 2011 Jun;11(6):403-15. doi: 10.1038/nri2974. Epub 2011 May 6.
9
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors.
Nat Med. 2010 Dec;16(12):1421-8. doi: 10.1038/nm.2250. Epub 2010 Nov 21.
10
Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Arch Pharm Res. 2010 Oct;33(10):1567-74. doi: 10.1007/s12272-010-1008-5. Epub 2010 Oct 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验